Chemocentryx Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CHEMOCENTRYX, and when can generic versions of CHEMOCENTRYX drugs launch?
CHEMOCENTRYX has one approved drug.
There are three US patents protecting CHEMOCENTRYX drugs.
There are sixty-six patent family members on CHEMOCENTRYX drugs in thirty-five countries and ten supplementary protection certificates in ten countries.
Summary for Chemocentryx
| International Patents: | 66 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Chemocentryx
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | 8,445,515 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | 8,906,938 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Chemocentryx Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 2381778 | ⤷ Try a Trial |
| Poland | 2585064 | ⤷ Try a Trial |
| Spain | 2577548 | ⤷ Try a Trial |
| Taiwan | I465434 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Chemocentryx Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2381778 | 2022C/518 | Belgium | ⤷ Try a Trial | PRODUCT NAME: TAVNEOS - AVACOPAN ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/21/1605 20220119 |
| 2381778 | 22C1020 | France | ⤷ Try a Trial | PRODUCT NAME: AVACOPAN ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1605 20220119 |
| 3508477 | PA2022006 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: AVAKOPANAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS ; REGISTRATION NO/DATE: EU/1/21/1605 20220111 |
| 2381778 | CA 2022 00022 | Denmark | ⤷ Try a Trial | PRODUCT NAME: AVACOPAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/21/1605 20220119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
